Abstract
ObjectivePhase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine the long-term causal effect of GLP1 agonists...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have